Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the ...

Following a surge of 52.47% during regular trading session on Tuesday, Polyrizon Ltd (NASDAQ: PLRZ) witnessed a dip of 12.02% ...

Investing.com -- Polyrizon Ltd. (NASDAQ: PLRZ) stock surged 41% following the announcement of encouraging preclinical results for its PL-14 Allergy Blocker, which demonstrated targeted deposition in ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...

RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ) has received approval from the Nasdaq Hearings Panel to maintain its listing on the Nasdaq Capital Market, the biotech company announced Tuesday ...

Polyrizon (PLRZ) said on Tuesday that it has received a notification letter from Nasdaq granting the company’s request for the continued listing of its securities on the Nasdaq Capital Market.

Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the 'Company” or 'Polyrizon”), a development stage biotech company specializing in the development of innovative ...

Polyrizon Ltd. (NASDAQ:PLRZ – Get Free Report) fell 2.2% on Thursday . The company traded as low as $0.69 and last traded at $0.70. 172,131 shares changed hands during mid-day trading, a decline ...

RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ) has received approval from the Nasdaq Hearings Panel to maintain its listing on the Nasdaq Capital Market, the biotech company announced Tuesday.

Polyrizon (PLRZ) said on Tuesday that it has received a notification letter from Nasdaq granting the company’s request for the continued listing of its securities on the Nasdaq Capital Market.

An update from Polyrizon Ltd. ( (PLRZ) ) is now available.